Chronic Migraine Is Associated With Reduced Household Income and Greater Headache Impact

CHICAGO, October 29, 2010 – New data presented today at The 2010 European Headache and Migraine Trust
International Congress (EHMTIC) shows that persons with chronic migraine
(headache on greater than or equal to 15 days per month) are much more likely
to have annual household incomes below US$30,000 than those with episodic
migraine (headache on < 15 days …. Source article  : Chronic Migraine Is Associated With Reduced Household Income and Greater Headache Impact.

Doctor to World Community: Eat Right and Thrive!

Joel Fuhrman, M.D., To Offer Message of Hope and Healing at London Scientific Conference

LONDON, October 28, 2010 – Joel Fuhrman, M.D., a world leader in nutritional science, will share his
discoveries leading to permanent weight loss and the reversal of chronic
health conditions such as heart disease, diabetes and high blood pressure now
threatening the world community …. Original source  : Doctor to World Community: Eat Right and Thrive!.

Taking Control of Diabetes: Support World Diabetes Day (14th November 2010)

LONDON, October 28, 2010 – Diabetic Hypoglycemia supports World Diabetes Day on the 14th November
2010 in raising the global awareness of diabetes (
www.worlddiabetesday.org/).

The theme of World Diabetes Day in 2010 is "Let's take control of
diabetes. Now", which marks the second year of the five-year focus on
diabetes education and prevention, the …. Source  : Taking Control of Diabetes: Support World Diabetes Day (14th November 2010).

Merck Serono Sells Th??ramex to Teva for EUR 265 Million

Acquisition Will Provide Teva With a Strong Platform to Expand its Global Women's Health Business

GENEVA, October 28, 2010 – Merck Serono, a division of Merck KGaA, Darmstadt, Germany,
announced today that it will sell Th??ramex, its Monaco-based pharmaceutical
company specialized in women's health and gynecology, to Teva. Merck KGaA and
Teva have signed an agreement whereby Teva …. Original article on Gaea Times at  : Merck Serono Sells Th??ramex to Teva for EUR 265 Million.

Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist

Potential Therapy for Lung Fibrosis of Scleroderma and Idiopathic Pulmonary Fibrosis

SAN DIEGO, October 28, 2010 – Amira Pharmaceuticals, Inc. announced today that it has initiated a Phase
1 clinical study with AM152, a novel LPA1 antagonist, in normal, healthy
subjects.
"We are excited to begin our journey exploring the therapeutic value of
AM152, a …. Original source  : Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist.

Pfizer’s Lyrica(R) (Pregabalin) Capsules CV Receives Approval for Treatment of Peripheral Neuropathic Pain In Japan

First Treatment Approved for Common Pain Conditions Filling Important Unmet Need for Patients in Japan

NEW YORK, October 28, 2010 – Pfizer Inc.(NYSE: PFE) announced today that the Japanese Ministry of
Health, Labour and Welfare approved Lyrica(R) (pregabalin) capsules for the
treatment of peripheral neuropathic pain. This follows the recent approval in
Japan of Lyrica for the treatment … Read more >>.